The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Novo Nordisk has struck back in its growing ... The OASIS 1 study showed that a once-daily, 50 mg dose of semaglutide achieved weight loss of 15% to 17% over a 68-week period.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products ... 10% weight loss at a daily dose of 50mg at 12 weeks, with patients taking 100mg per day ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Novo Nordisk, a leading global healthcare company, announced that the US Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg ...

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...